The physiological effect of breast cancer on activity of aromatase enzyme and some concentrations of hormones and biochemical in the women in Baghdad city
Article Sidebar
Main Article Content
Abstract
This study was conducted to investigate the effect of women breast cancer on some hormones (Estrogen, Testosterone, prolactin) and biochemical parameters (Glucose, Cholesterol, Aromatase). The study is done in Medical City Teaching Hospital in Baghdad to show the effect of age, body weight and type of feeding for women with breast cancer and compared with healthy women. Their age ranged between (24-70) years for both groups. The results showing high significant effects of all parameters study in cancer disease women compared with healthy. All Study parameters increased with the advance of age and with the increased in body mass index. The breast cancer was spread in women artificial infant feeding compared with natural feeding .The conclusion suggested that the increase in estrogen, testosterone, prolactin, aromatase, cholesterol and glucose when the women have breast cancer.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1- Peter B, Bernard L. (2008). editors. World Cancer Report 2008 [online]. WHO press. (2008). The International Agency for Research on Cancer (IARC). Available rompdfs_online/wrc/2008/wcr_.pdf. [cited 17 June 2011].
2- Siegel R, Naishadham MA, Jemal A. (2013). Cancer statistics, .Ca Cancer J Clin2013;63:11-30.
3- Cleries, R. et al. (2006). The trends of breast cancer mortality in Spain during the period 1977-2001 and Bagesian approach for progection during 2002-2016 . Ann. Oncol. 17(2): 1783-1791 .
4- Smith, IE. And Dowsett, M. (2003). Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348: 2431-2442.
5- Madigan, MP.; Ziegler, RG.; Benichou, J.; Byrne, C. and Hoover RN. (1995). Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst, 87, 1681-1685.
6- Lai, LC. (2002). Role of steroid hormones and growth factors in breast cancer. Clinical Chemistry and Laboratory Medicine, 10: 969-974.
7- Neville, MC.; McFadden, TB. and Forsyth, I. (2002). Hormonal regulation of mammary differentiation and milk secretion. Journal of Mammary Gland Biology and Neoplasia, 1: 49-66.
8- Casellas-Grau, A.; Font, A. and Vives, J. (2014). Positive psychology interventions in breast cancer.A systematic review. Psycho-Oncology, 23:9-19.
9- Basu, A.; Rowan, BG.; Basu, A.; Rowan, BG. (2005). Genes related to estrogen action in reproduction and breast cancer. [Review] [277 refs]. Frontiers in Bioscience .10:2346-72.
10- Darbre, PD. and Darbre PD. (2006). Environmental oestrogens, cosmetics and breast cancer. [Review] [159 refs]. Best Practice and Research Clinical Endocrinology &Metabolism. 20 (1):121-43.
12- Grundy, SM. (2007). Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 92 (2):399-404.
13- Esposito, K.; Chiodini, P.; Colao, A.; Lenzi, A. and Giugliano D. (2012). Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 35 (11):2402-2411.
14- de Azambuja, E.; Cardoso, F.; de Castro, G. Jr.; Colozza, M.; Mano, MS.; Durbecq, V.; Sotiriou, C.; Larsimont, D.; Piccart-Gebhart, MJ. and Paesmans, M. (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. British Journal of Cancer 96 1504–1513.
15- Ma, X.; Qi, X.; Chen, C.; Lin, H.; Xiong, H.; Li, Y.; Jiang, J. (2010). Association between CYP1 polymorphisms and breast cancer risk: Results from 10,592 cases and 11,720 controls. Breast Cancer Res. Treat. 122, 495-501 Kagawa N, Hori H, Waterman MR, Yoshioka S. Characterization of stable human aromata expressed in E. coli. Steroids. 69(4):235 -243. [PubMed: 15183689].
16- Germain, D.R.; Graham, K.; Glubrecht, D.D.; Hugh, J.C.; Mackey, J.R. and Godbout, R. (2011). ”DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer.” Breast Cancer Res Treat., 127(1):53-63.
17- Trentham-Dietz, A.; Newcomb, PA.; Egan, K. M. (2000). Titus-Ernstoff L, Baron JA, Storer BE, Stampfer M, Willett WC: Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control 11:533- 542.
18- McTiernan, A. (2005). Obesity and cancer: the risks, science, and potential management strategies. Oncology. 19: 871? 881.
19- Yakar, S.; Leroith, D.; Brodt, P. (2005). The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407- 420.
20- Mai, K.; Bobbert, T.; Kullmann, V.; Andres, J.; Rochlitz, H.; Osterhoff, M.; Weickert, MO.; Bahr, V.; Mohling, M.; Pfeiffer, AF.; Diederich, S. and Spranger, J. (2006). Free fatty acids increase androg precursors in vivo. J Clin Endocrinol Metab 91: 1501-1507.
21- Tang, X.; Ma, H.; Zou, S. and Chen, W. (2007). Effects of dehydroepiandrosterone (DHEA) on hepatic lipid metabolis parameters and lipogenic
mRNA expression in broiler chickens. Lipids 42: 1025-1033.
22- Lasco, A.; Frisina, N.; Morabito, N.; Gaudio, A.; Morini, E.; Trifiletti, A; Basile, NICITA-MAURO V. and Cucinotta, D. (2001). Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 145: 457-461.
23- Abdulrazak, H. and Al-Tae'e, N. K. (2007). Polycystic overian syndrome : The correlation between the LH/FSH ratio and disease manifestation. Middle Est Fertility Society Journal. 12(1):35-40.
24- Hankinson, SE.; Manson, JE.; Spiegelman, D.; Willett, WC.; Longcope, C. and Speizer, FE. (1996). Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev. 1996;4:649-54.
25- Michels, KB.; Solomon, CG.; Hu, FB.; et al. (2003). Type 2 diabetes and subsequent incidence of breast cancer in the Nurses? Health Study. Diabetes Care, 26, 1752-8.
26- Liao, SS.; Li, J.; Wei, W.; et al. (2011). Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev, 12, 1061-1065.
27- Hamelers, IH. and Steenbergh. PH. (2003). Interactions between estrogen and insulin-like growth factor signaling pathways in Alvaro L Ronco, et al., human breast tumor cells. Endocr Relat Cancer, 10, 331? 45.
28- Cnop, M.; Havel, PJ.; Utzschneider, KM.; Carr, DB.; Sinha, MK.; Boyko, EJ.; Retzlaff, BM.; Knopp, RH.; Brunzell, JD. and Kahn, SE. (2003). Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 46(4):459-469.
29- Abbasi, F.; Chu, JW.; Lamendola, C.; McLaughlin, T.; Hayden, J.; Reaven, GM. and Reaven, (2004). Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes. 53(3):585-590.
30- Lara-Castro, C.; Fu, Y.; Chung, BH. and Garvey, W. (2007). Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007; 18(3):263-270.
31- Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, et al. (2004) Polymorphisms associated with circulating sex hormone levels in postmeno- pausal women. Journal of the National Cancer Institute 96: 936-945.
32- Thomas, HV.; Reeves, GK. and Key, TJ. (1997). Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control. 1997;8:922-8.
33- Eliassen, AH.; Tworoger, SS. and Hankinson, SE. (2007). Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in
premenopausal and postmenopausal women. Int J Cancer 120:1536 - 1541.
34- Ewertz, M.; Jensen, MB.; Gunnarsdo, KA.; H jris, I.; Jakobsen, EH.; Nielsen, D.; Stenbygaard, LE.; Tange, UB. and Cold, S. (2011). Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29: 25–31.
35- Renehan, AG.; Tyson, M.; Egger, M.; Heller, RF. and Zwahlen M. (2008). Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371: 569–578.
36- Pollheimer, MJ.; Kornprat, P.; Lindtner, RA.; Harbaum, L.; Schlemmer, A.; Rehak, P. ;et al. (2010). Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol. 41:1749?57.
37- De Gonzalo-Calvo, et al. (2015) . BMC Cancer 15:460 DOI 10.1186/s12885-015-1469-5.
38- Kagawa, N.; Hori, H.; Waterman, MR.; Yoshioka, S. (2004). Characterization of stable human Aromatase expressed in E. coli. Steroids. 69(4):235-243. [PubMed: 15183689.
39- Kao, YC.; Korzekwa, KR.; Laughton, CA. and Chen, S. (2001). Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. Eur J Biochem. 268(2):243?251. [PubMed: 11168357.
40- Fuhrman, C.; Fleury, B.; Nguy^en, X. L. and Delmas, M.-C. (2011). Symptoms of sleep apnoea syndrome: high prevalence and under-diagnosis in the French population. Sleep Med., 2012, 13: 852–858.Fuller, J. M., Wong, K. K., Krass, I., Grunstein, R. and Saini, B. Sleep disorders screening, sleep health awareness, and patient follow-up by community pharmacists in Australia. Patient Educ. Couns., 2011, 83: 325–335
41- Muggerud, A. A.; Hallett, M., Johnsen, H.; Kleivi, K. and Zhou, W. (2010). Tahmasebpoor S,et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol. 2010;4:357?68.
42- Tikk, K.; Sookthai, D.; Johnson, T.; Rinaldi, S.; Romieu. I.; Tjnneland, A.; et al. (2014). Circulating prolactin and breast cancer risk among pre- and
postmenopausalwomen in the EPIC cohort. Ann Oncol. 25:1422- 8 .
43- Lipworth, L. ; Bailey, L. R. and Trichopoulos, D. (2000). History of breast-feeding in relation to breast cancer risk: A review of the epidemiologic literature. Journal of the National Cancer Institute, 92(4), 302-312.
44- Ryan, CP.; Anderson, WG.; Berkvens, CN. and Hare, JF.(2014). Maternal Gestational Cortisol and Testosterone Are Associated with Trade-Offs in Offspring Sex and Number in a Free-Living Rodent (Urocite llusrichard sonii).PLoS.ONE9(10):e111052. oi:10.1371/journal.pone.0111052.
45- Schwanz, LE. and Robert, KA. (2014). Proximate and ultimate explanations of mammalian sex allocation in a marsupial model. Behav Ecol Sociobiol. 68:1085-1096.
46- Ochedalski, T.; Subburaju, S.; Wynn, PC.; Aguilera, G. (2007). Interaction between oestrogen and oxytocin on hypothalamic-pituitary-adrenal axis activity. Neuroendocrinol 19:189 - 97.
47- Champagne, F., Diorio, J.; Sharma, S. and Meaney, MJ. (2001). Naturally occurring variationsnin maternal behavior in the rat are associated with differences in estro-gen-inducible central oxytocin receptors. Proc Natl Acad Sci U S A (2001)98:12736-41.
48- Serova, LI.; Harris, HA.; Maharjan, S. and Sabban, EL.(2010). Modulation of responses to stress by estradiol benzoate and selective estrogen receptor agonists.J. of Endocrinol. (2010) 205:253-62.
49- Liu, J. ; Bisschop, PH.; Eggels, L.; Foppen, E.; Fliers, E.; Zhou, JN.; et al. (2011). Intrahypothalamic estradiol modulates hypothalamus-pituitary-adrenal-axis activity in female rats. Endocrinology (2012) 153:3337- 44.
50- Lee, HJ. and Ormandy, CJ. (2012). Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol 2012; 357:101-107.
51- Tworoger, SS.; Eliassen, AH.; Zhang, X.; Qian, J.; Sluss, PM.; Rosner, BA.; et al. (2013). A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 73:4810- 9.